LivaNova PLC (NASDAQ:LIVN) Given Average Rating of “Buy” by Analysts

Shares of LivaNova PLC (NASDAQ:LIVN) have been assigned an average rating of “Buy” from the six ratings firms that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $70.80.

LIVN has been the topic of a number of recent research reports. Needham & Company LLC lifted their target price on LivaNova from $72.00 to $75.00 and gave the company a “buy” rating in a research report on Wednesday, July 31st. Baird R W raised LivaNova from a “hold” rating to a “strong-buy” rating in a research report on Tuesday. Robert W. Baird raised LivaNova from a “neutral” rating to an “outperform” rating and increased their price objective for the company from $55.00 to $66.00 in a report on Tuesday. Finally, Stifel Nicolaus boosted their target price on shares of LivaNova from $70.00 to $72.00 and gave the stock a “buy” rating in a report on Thursday, July 25th.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Primecap Management Co. CA increased its position in shares of LivaNova by 0.7% during the second quarter. Primecap Management Co. CA now owns 5,981,200 shares of the company’s stock worth $327,889,000 after buying an additional 44,049 shares during the period. Vanguard Group Inc. raised its position in shares of LivaNova by 3.5% in the 1st quarter. Vanguard Group Inc. now owns 1,832,987 shares of the company’s stock worth $102,537,000 after acquiring an additional 62,480 shares in the last quarter. Point72 Asset Management L.P. lifted its stake in shares of LivaNova by 204.3% in the 2nd quarter. Point72 Asset Management L.P. now owns 1,285,636 shares of the company’s stock valued at $70,479,000 after purchasing an additional 863,157 shares during the period. Dimensional Fund Advisors LP lifted its stake in shares of LivaNova by 6.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,241,985 shares of the company’s stock valued at $64,262,000 after purchasing an additional 74,067 shares during the period. Finally, Greenlight Capital Inc. boosted its position in shares of LivaNova by 3.5% during the 4th quarter. Greenlight Capital Inc. now owns 1,229,316 shares of the company’s stock valued at $63,605,000 after purchasing an additional 42,040 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

LivaNova Price Performance

LivaNova stock opened at $51.07 on Thursday. The company has a current ratio of 3.45, a quick ratio of 2.94 and a debt-to-equity ratio of 0.49. The firm has a market capitalization of $2.77 billion, a P/E ratio of -85.12 and a beta of 1.00. The business has a 50-day moving average of $48.88 and a 200-day moving average of $53.42. LivaNova has a 1 year low of $42.75 and a 1 year high of $64.47.

LivaNova (NASDAQ:LIVN) last released its quarterly earnings results on Wednesday, July 31st. The company reported $0.81 EPS for the quarter, topping analysts’ consensus estimates of $0.66 by $0.15. LivaNova had a positive return on equity of 13.77% and a negative net margin of 1.37%. The company had revenue of $318.60 million for the quarter, compared to analyst estimates of $305.05 million. On average, equities analysts anticipate that LivaNova will post 2.58 EPS for the current year.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.